

Nancy A Kernan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7859343/publications.pdf>

Version: 2024-02-01

148
papers

10,677
citations

36303

51
h-index

31849

101
g-index

148
all docs

148
docs citations

148
times ranked

7192
citing authors

#	ARTICLE	IF	CITATIONS
1	Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 1994, 330, 1185-1191.	27.0	1,040
2	Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program. <i>New England Journal of Medicine</i> , 1993, 328, 593-602.	27.0	835
3	Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. <i>Blood</i> , 2001, 98, 2043-2051.	1.4	631
4	Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 157-168.	2.0	509
5	Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2644-2656.	1.4	389
6	Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. <i>Blood</i> , 2008, 112, 4318-4327.	1.4	283
7	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	1.4	255
8	Allogeneic Bone Marrow Transplantation after Hyperfractionated Total-Body Irradiation and Cyclophosphamide in Children with Acute Leukemia. <i>New England Journal of Medicine</i> , 1987, 317, 1618-1624.	27.0	235
9	Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II&III trial. <i>Lancet</i> , The, 2005, 366, 733-741.	13.7	227
10	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1005-1017.	2.0	227
11	T-Cell"Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. <i>Blood</i> , 1998, 91, 1083-1090.	1.4	217
12	Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. <i>Blood</i> , 2000, 95, 2219-2225.	1.4	212
13	Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. <i>Blood</i> , 2000, 96, 4096-4102.	1.4	191
14	Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. <i>Blood</i> , 2002, 99, 1971-1977.	1.4	191
15	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	1.4	190
16	Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 184-194.	2.0	178
17	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	8.2	161
18	Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell"Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1487-1498.	2.0	148

#	ARTICLE	IF	CITATIONS
19	Successful Immune Reconstitution Decreases Leukemic Relapse and Improves Survival in Recipients of Unrelated Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 919-927.	2.0	147
20	Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1541-1548.	2.0	145
21	A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1469-1476.	2.0	126
22	Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. <i>Blood</i> , 2011, 117, 3277-3285.	1.4	121
23	Cord Blood Units with Low CD34+ Cell Viability Have a Low Probability of Engraftment after Double Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 500-508.	2.0	118
24	Successful treatment of metastatic retinoblastoma. <i>Cancer</i> , 2000, 89, 2117-2121.	4.1	116
25	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , 2015, 125, 199-205.	1.4	109
26	The National Marrow Donor Program 20 Years of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 2-7.	2.0	107
27	T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. <i>Blood</i> , 2007, 110, 4552-4559.	1.4	106
28	HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 1644-1652.	1.6	100
29	Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. <i>Blood</i> , 2005, 106, 3308-3313.	1.4	99
30	Cord Blood Transplantation Study (COBLT): Cord Blood Bank Standard Operating Procedures. <i>Stem Cells and Development</i> , 1998, 7, 521-561.	1.0	97
31	Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. <i>Transfusion</i> , 2005, 45, 856-866.	1.6	95
32	Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 16-22.	2.0	95
33	Ex Vivo T Cell-Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 898-903.	2.0	95
34	Final results from a defibrotide treatment IND study for patients with hepatic venoocclusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	2.5	95
35	Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. <i>Transfusion</i> , 2005, 45, 842-855.	1.6	87
36	Fludarabine-based cytoreductive regimen and T cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. <i>British Journal of Haematology</i> , 2008, 140, 644-655.	2.5	79

#	ARTICLE	IF	CITATIONS
37	Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young Children: The Cord Blood Transplantation Study (COBLT) Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 637-646.	2.0	76
38	T Cell-Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1335-1342.	2.0	74
39	Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. <i>Blood</i> , 2014, 124, 2905-2912.	1.4	74
40	Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1316-1326.	2.0	72
41	Drug safety evaluation of defibrotide. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 123-136.	2.4	72
42	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 112-118.	2.5	72
43	Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 55-59.	1.5	71
44	Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. <i>Blood</i> , 2017, 129, 2308-2315.	1.4	71
45	Antigen-Specific T-Lymphocyte Function After Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1335-1342.	2.0	70
46	Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. <i>Blood</i> , 2006, 108, 2470-2475.	1.4	70
47	Transplantation in Remission Improves the Disease-Free Survival of Patients with Advanced Myelodysplastic Syndromes Treated with Myeloablative T Cell-Depleted Stem Cell Transplants from HLA-Identical Siblings. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 458-468.	2.0	64
48	A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 799-803.	2.0	63
49	Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 512-518.	2.0	62
50	Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1022-1030.	2.0	58
51	Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. <i>Blood Advances</i> , 2019, 3, 939-944.	5.2	56
52	Successful Treatment of Human Herpesvirus 6 Encephalitis in a Bone Marrow Transplant Recipient. <i>Clinical Infectious Diseases</i> , 1998, 27, 653-654.	5.8	55
53	Safety and Immunogenicity of the Live Attenuated Varicella Vaccine Following T Replete or T Cell-Depleted Related and Unrelated Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1708-1713.	2.0	54
54	Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2017, 58, 1859-1871.	1.3	54

#	ARTICLE	IF	CITATIONS
55	Individual Physician Practice Variation in Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 2162-2170.	1.6	52
56	Variation in Supportive Care Practices in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1231-1238.	2.0	51
57	Unrelated Donor Bone Marrow Transplantation for Children With Acute Myeloid Leukemia Beyond First Remission or Refractory to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 4326-4332.	1.6	51
58	COMPARISON OF CAMPATH-1 PLUS COMPLEMENT, ANTI-T CELL RICIN A CHAIN IMMUNOTOXIN, AND SOYBEAN AGGLUTININ ALONE OR IN COMBINATION WITH SHEEP ERYTHROCYTES OR IMMUNOMAGNETIC BEADS. Transplantation, 1989, 47, 984-988.	1.0	50
59	QUANTITATION OF T LYMPHOCYTES IN HUMAN BONE MARROW BY A LIMITING DILUTION ASSAY. Transplantation, 1985, 40, 317-322.	1.0	48
60	Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1313-1323.	2.0	48
61	Defibrotide for Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 997-1004.	2.0	47
62	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2012, 5, 291-302.	2.2	44
63	Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 360-366.	2.0	43
64	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 787-793.	2.0	43
65	Safety and Immunogenicity of the Tetravalent Protein-Conjugated Meningococcal Vaccine (MCV4) in Recipients of Related and Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 145-149.	2.0	41
66	T Cell-Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 208-213.	2.0	41
67	Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. <i>British Journal of Haematology</i> , 2000, 111, 1153-1157.	2.5	41
68	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1985-1993.	2.0	40
69	Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 2018-2024.	1.5	38
70	Ex Vivo CD34+ Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 452-458.	2.0	35
71	LUNG TRANSPLANTATION AFTER ALLOGENEIC MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS. Transplantation, 2001, 72, 1986-1990.	1.0	34
72	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 920-925.	2.0	33

#	ARTICLE	IF	CITATIONS
73	Paroxysmal nocturnal hemoglobinuria in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2012, 59, 525-529.	1.5	32
74	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2160-2166.	2.0	31
75	Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1799-1805.	1.3	30
76	Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 475-482.	2.0	29
77	Long-term medical outcomes in survivors of extraocular retinoblastoma: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. <i>Pediatric Blood and Cancer</i> , 2013, 60, 694-699.	1.5	27
78	Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. <i>Cytotherapy</i> , 2020, 22, 503-510.	0.7	27
79	Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients with Treatment-Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 473-480.	2.0	26
80	Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 235-244.	2.0	25
81	Defibrotide for the treatment of hepatic venoocclusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded access program. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27269.	1.5	25
82	Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. <i>Haematologica</i> , 2012, 97, 344-352.	3.5	24
83	Sustained Donor Engraftment in Recipients of Double-Unit Cord Blood Transplantation Is Possible Despite Donor-Specific Human Leukocyte Antigen Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 735-739.	2.0	21
84	Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor. <i>Sarcoma</i> , 2015, 2015, 1-9.	1.3	21
85	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 72.e1-72.e8.	1.2	21
86	Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1342-1349.	2.0	19
87	No Wash Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation is Safe with High Rates of Sustained Donor Engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 490-494.	2.0	18
88	The Use of Back-up Units to Enhance the Safety of Unrelated Donor Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 648-651.	2.0	17
89	Juvenile-Onset Recurrent Respiratory Papillomatosis Involving the Lung: A Case Report and Review of the Literature. <i>Pediatric and Developmental Pathology</i> , 1998, 1, 157-163.	1.0	16
90	Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1879-1886.	2.0	16

#	ARTICLE	IF	CITATIONS
91	Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 337-340.	1.3	16
92	Treatment of Childhood Acute Nonlymphoblastic Leukemia: A Review. <i>Cancer Investigation</i> , 1993, 11, 534-553.	1.3	15
93	Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1057-1062.	2.0	15
94	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1861-1870.	1.3	12
95	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. <i>Blood</i> , 2009, 114, 654-654.	1.4	12
96	Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1054-1063.	5.2	12
97	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2160-2169.	2.4	11
98	Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL. <i>Blood</i> , 2015, 126, 2533-2533.	1.4	10
99	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2088-2095.	2.0	9
100	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 583-587.	2.5	9
101	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1449-1454.	2.0	8
102	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021, 56, 2889-2896.	2.4	8
103	Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.. <i>Blood</i> , 2007, 110, 2991-2991.	1.4	8
104	Splenic infarction and subsequent splenic rupture in a patient with paroxysmal nocturnal hemoglobinuria and heparin-induced thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2009, 53, 472-474.	1.5	6
105	Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.. <i>Blood</i> , 2009, 114, 2296-2296.	1.4	6
106	CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT. <i>Blood</i> , 2012, 120, 353-353.	1.4	6
107	Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2017, 130, 747-747.	1.4	6
108	Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2016, 128, 61-61.	1.4	5

#	ARTICLE	IF	CITATIONS
109	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 88.e1-88.e6.	1.2	4
110	Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplantation, 2021, 56, 2997-3007.	2.4	4
111	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 1095-1100.	2.4	4
112	Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cyoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. British Journal of Haematology, 2000, 111, 1153-1157.	2.5	3
113	Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cyoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or mismatched donors. Pediatric Hematology and Oncology, 2016, 33, 347-358.	0.8	3
114	Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using Low-dose Cyclophosphamide, ATG Plus Fludarabine. Journal of Pediatric Hematology/Oncology, 2018, 40, e220-e224.	0.6	3
115	Immunogenicity of Haemophilus Influenza and Pneumococcal Vaccines in Related and Unrelated Transplant Recipients.. Blood, 2006, 108, 592-592.	1.4	3

116

#	ARTICLE	IF	CITATIONS
127	High Day 28 ST2 Biomarker Levels Predict Severe Day 100 Acute Graft-Versus-Host Disease and Day 180 Transplant-Related Mortality after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S278-S279.	2.0	1
128	High Dose Busulfan and Fludarabine with Anti-Thymocyte Globulin (ATG) Followed by Unmodified Marrow Grafts from HLA-Matched Siblings for the Treatment of High Risk Hemoglobinopathies (HGBpathies).. <i>Blood</i> , 2005, 106, 2032-2032.	1.4	1
129	Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report.. <i>Blood</i> , 2005, 106, 2046-2046.	1.4	1
130	Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice. <i>Blood</i> , 2010, 116, 2092-2092.	1.4	1
131	Adoptive Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides of the CMV-pp65 Protein for the Treatment of Persistent CMV Antigenemia Following Allogeneic Hematopoietic Stem Cell Transplants. <i>Blood</i> , 2012, 120, 351-351.	1.4	1
132	Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients. <i>Blood</i> , 2013, 122, 3297-3297.	1.4	1
133	Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10513-10513.	1.6	1
134	Allogeneic or Autologous Stem Cell Transplantation (SCT) for the Treatment of Pediatric Patients with Non-Hodgkins Lymphoma (NHL).. <i>Blood</i> , 2005, 106, 2093-2093.	1.4	0
135	Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients: Review of a Single Center Series. <i>Blood</i> , 2010, 116, 2231-2231.	1.4	0
136	Adoptive Immune Cell Therapy Using Third Party T-Cell Donors In the Treatment of EBV Related Diseases In Immunodeficient Recipients. <i>Blood</i> , 2010, 116, 487-487.	1.4	0
137	A Phase I-II Dose Escalation Trial of Clofarabine Plus Melphalan and Thiotepa Followed by Unmodified Allogeneic Stem Cell Transplant (SCT) for the Treatment of High Risk or Advanced Acute Leukemia. <i>Blood</i> , 2010, 116, 2354-2354.	1.4	0
138	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with Treatment Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia (tMDS/AML). <i>Blood</i> , 2010, 116, 2363-2363.	1.4	0
139	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for the Treatment of Children with Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) In First Remission (CR1). <i>Blood</i> , 2010, 116, 3546-3546.	1.4	0
140	A Novel Reduced Intensity Conditioning Can Induce a High Incidence of Sustained Donor Engraftment After Double Unit Cord Blood Transplantation (CBT) without Anti-Thymocyte Globulin. <i>Blood</i> , 2010, 116, 2351-2351.	1.4	0
141	Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience. <i>Blood</i> , 2012, 120, 1996-1996.	1.4	0
142	Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines. <i>Blood</i> , 2015, 126, 3157-3157.	1.4	0
143	T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1 or CR2 or MDS Including tMDS/AML. <i>Blood</i> , 2015, 126, 5513-5513.	1.4	0
144	Despite Increasing Size of Unrelated Donor (URD) Registries and the Global Cord Blood (CB) Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients. <i>Blood</i> , 2016, 128, 821-821.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Evaluation of Cord Blood (CB) Unit TNC & CD34+ Cell Content & Donor-Recipient High-Resolution 8 HLA-Allele Match By Patient Ancestry: An Evaluation of 513 CB Units in a Racially & Ethnically Diverse Population of Adults with Hematologic Malignancies. Blood, 2018, 132, 3342-3342.	1.4	0
146	Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL. Blood, 2019, 134, 4582-4582.	1.4	0
147	Sinusoidal Obstruction Syndrome/Hepatic Venous Occlusive Disease. , 2022, , 143-163.		0
148	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. Blood, 2020, 136, 30-31.	1.4	0